Joseph Thome, an analyst from TD Cowen, maintained the Buy rating on United Therapeutics. The associated price target was raised to $525.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Thome has given his Buy rating due to a combination of factors that highlight United Therapeutics’ strong growth potential despite some recent setbacks. The company’s Q3 revenues were slightly below expectations, but management expressed confidence in the current product portfolio’s ability to drive growth, aiming for a $4 billion revenue run rate by 2027. This optimism is bolstered by the potential of the IPF program and the anticipated Phase III data in the first half of 2026.
Moreover, while Tyvaso sales missed expectations, the management’s interest in exploring partnerships for Tyvaso in IPF and ralinepag for PAH suggests strategic initiatives that could enhance future growth. Although there might be short-term volatility due to the Yutrepia launch, the company’s confidence in its product offerings and the strong patient shipments for Tyvaso provide a solid foundation for long-term success. These factors collectively underpin Thome’s Buy rating for United Therapeutics.
In another report released on October 23, RBC Capital also reiterated a Buy rating on the stock with a $569.00 price target.
Based on the recent corporate insider activity of 188 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of UTHR in relation to earlier this year.